a public good project by the
Synthesis
Company
of California

© 2026

Julio Rosenstock | doi.page

0 works0 citations0 h-index

Julio Rosenstock

Velocity Clinical Research (United States)(US)

Publications by Year

Research Areas

Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Pharmacology and Obesity Treatment

Most-Cited Works

→ Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes(2016)6,312 cited
→ Once-Weekly Semaglutide in Adults with Overweight or Obesity(2021)4,025 cited
→ Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes(2021)1,723 cited
→ Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)(2009)1,482 cited
→ The Treat-to-Target Trial(2003)1,472 cited
→ Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials(2021)1,414 cited
→

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients

(2006)

1,218 cited

→ Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial(2021)1,195 cited

→ Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea(2005)1,174 cited

→ Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity(2021)1,132 cited